our products
our products
information_top

Call us at:

(818)591-3030

USA

Click here to send us an email
tel_section

Diagnostic Automation Question & AnswerDiagnostic Automation Question & Answer Diagnostic Automation Articles Diagnostic Automation kit images Diagnostic Automation videos


Pregnancy Rapid tests

Epstein Barr Virus VCA IgM (EBV, VCA IgM) ELISA kit

Name

Epstein Barr Virus VCA IgM (EBV, VCA IgM) ELISA kit

Full name

Human Epstein Barr Virus VCA IgM (EBV, VCA IgM) ELISA Test Kit

Category Name Infectious Disease ELISA kits
Test 96
Method ELISA method: Enzyme Linked Immunosorbent Assay
Principle Indirect : Antigen Coated Plate
Detection Range Qualitative elisa assay- Positive, Negative and Cut-off
Sample 10ul serum
Specificity 93.2%
Sensitivity 90.9%
Total Time ~90 min
Shelf Life 12 Months from the manufacturing date

Item #:                    1406-2   Quantity:               

Epstein Barr Virus VCA IgM (EBV, VCA IgM) ELISA kit


Epstein Barr Virus VCA IgM (EBV, VCA IgM) ELISA kit

callback phone number email us


Epstein Barr Virus VCA IgM (EBV, VCA IgM) ELISA kit description:




Diagnostic Automation Epstein-Barr Virus-Viral Capsid Antigen (EBV-VCA) IgM Enzyme-linked Immunosorbent Assay (ELISA), is intended for the detection of IgM antibody to Epstein-Barr virus in human serum.



Materials Provided with EBV, VCA IgM ELISA kit:
1. Microwell strips: 125kD capsid peptide coated wells
2. Conjugate: Conjugated HRP-goat anti-human IgM
3. Positive Control (Human Serum)
4. Calibrator (Human Serum)
5. Negative Control (Human Serum)
6. Sample Diluent
7. TMB
8. Stop Solution
9. Wash Buffer Concentrate (10X)

Materials required but not provided:
1. Freshly distilled or deionized water
2. Dispensing system and/or pipette
3. EIA kit Microplate washer
4. EIA kit Microplate Reader with 450nm wavelength



EBV, VCA IgM ELISA Test Background Information:
EBV is classified as a member of the herpes-virus family based upon its characteristic morphology. EBV infection may demonstrate a wide spectrum of clinical symptoms. The majority of primary EBV infections is transmitted via saliva, occurs during childhood, and is subclinical. Antibody titers to specific EBV antigens correlate with different stages of IM. Both IgM and IgG antibodies to the viral capsid antigen (VCA) peak 3 to 4 weeks after primary EBV infection. IgM anti-VCA declines rapidly and is usually undetectable after 12 weeks. IgG anti-VCA titers decline slowly after peaking but last indefinitely. Antibodies to EBV nuclear antigen (EBNA) detected by anti-complement immunofluorescence develop from 1 month to 6 months after infection; and, like anti-VCA, persist indefinitely. Antibodies to EBNA indicate that the EBV infection was not recent. Antibodies to EA may appear transiently for up to three months or longer during the acute phase of IM in 85% of patients. Elevated levels of anti-EA and IgG anti-VCA may be detected in patients with chronic or recurrent illness suspected of being caused by EBV. However, a diagnosis of chronic EBV should not be based on the presence of antibodies to EA since elevated anti-EA titers may also be found in patients with other diseases as well as in healthy individuals with past EBV infections.



EBV, VCA IgM ELISA Test Principle:
Purified EBV-VCA antigen is coated on the surface of microwells. Diluted patient serum is added to wells, and the EBV-VCA IgM specific antibody, if present, binds to the antigen. All unbound materials are washed away. After adding enzyme conjugate, it binds to the antibody-antigen complex. Excess enzyme conjugate is washed off, and TMB Chromogenic substrate is added. The enzyme conjugate catalytic reaction is stopped at a specific time.


For more information about ELISA Kits, Rapid Tests, IFA Kits, CLIA Test Kits, or Serology tests, please see our website home page, or contact our Customer Service Representative at 818-591-3030.




Product Note:

Antibody titers to specific EBV antigens correlate with different stages of IM. Both IgM and IgG antibodies to the Viral Capsid Antigen (VCA) peak three to four weeks after primary EBV infection. IgM anti-VCA decline rapidly and is usually undetectable after 12 weeks. IgG anti-VCA titers decline slowly after peaking but last indefinitely. Antibodies to EBV Nuclear Antigen (EBNA) develop from one to six months after infection and, like anti-VCA, persist indefinitely. Antibodies to EBNA indicate that the infection was not recent.